FlyteHealth achieves significant weight loss results, averaging 15.8% with non-GLP-1s and further improvements with GLP-1s. In this episode, Saul Marquez hosts Gabe Castaneda, Chief Revenue Officer at FlyteHealth, to talk about advancements and issues in obesity management, particularly focusing on GLP-1 medications. With 25 years of healthcare experience, Gabe highlights FlyteHealth’s innovative approach combining lifestyle management with clinical medication management. FlyteHealth's patented algorithm delivers personalized care, often utilizing non-GLP-1s to reduce costs and avoid side effects and aiming for sustainable weight loss. He also discusses the company's strategic partnerships and expansion plans, advocates for avoiding GLP-1s, and warns against compound prescriptions. Tune in to discover how FlyteHealth is revolutionizing obesity management with innovative solutions!
About Gabe Castaneda:
Gabe Castaneda is the Chief Revenue Officer at FlyteHealth, bringing over 25 years of experience in sales, marketing, and customer success in both business-to-business and direct-to-consumer markets. He has held significant roles at Omada Health, Blue Cross and Blue Shield, and UnitedHealth Group. Gabe holds a bachelor's degree in marketing from the University of Minnesota, a law degree from the Mitchell Hamline School of Law, and an MBA from the Thunderbird School of Global Management. His expertise lies in developing strategic sales and marketing organizations, reducing costs, improving health outcomes, and increasing member engagement.
Things You’ll Learn:
Resources: